In this review we summarize the recent evidence that highlights the involvement of low-grade inflammation in the development and pathophysiology of hypertension.
Introduction
Vascular wall inflammation plays a key role in the pathogenesis and progression of atherosclerosis, cardiovascular disease and hypertension [1] [2] [3] [4] . Essential hypertension is characterized by increased peripheral vascular resistance to blood flow [5] . This resistance results mostly from energy dissipation in small arteries and arterioles [6] . Resistance arteries may play an important role in the development [7] , and may contribute to the complications of hypertension [8] . Small decreases in the lumen of the small arteries significantly increase resistance. In hypertension, resistance arteries undergo vascular remodeling (reduced lumen with increased media width) that may be structural, mechanical or functional. Extracellular matrix deposition and inflammation are critically involved in vascular remodeling. With chronic vasoconstriction [due to the influence of myogenic tone, the renin-angiotensin-aldosterone system (RAAS), catecholamines and growth factors], vessels may became embedded in the remodeled extracellular matrix and may not return to their vasodilated state [9] . Isolated systolic hypertension results from age-associated vascular stiffening and reduced compliance [10] . Arterial stiffness increases with advancing age and in the presence of other cardiovascular risk factors, including hypertension, the metabolic syndrome, diabetes, obesity, hypercholesterolemia, and elevated levels of C-reactive protein (CRP). Arterial stiffness is significantly and independently associated with both target organ damage and increased risk for cardiovascular morbidity and mortality [11, 12] . The mechanisms underlying age-and diseaserelated arterial stiffening are not fully understood; however, assessment of changes in gene expression associated with increased arterial stiffness and gene polymorphisms that increase the risk for vascular stiffening suggests that components of the RAAS, matrix metalloproteinases, intracellular signaling and extracellular matrix components may all be involved in this process [13] .
Elevated levels of blood pressure may induce a proinflammatory response. Hypertension accentuates the progression of atherosclerosis that has an inflammatory component which plays an integral role in its pathogenesis [14] , and which is also present in other conditions associated with cardiovascular events, such as hypertension [15] and diabetes mellitus [16] . Indeed, inflammation is now recognized as a central mechanism contributing to progression of cardiovascular disease in general, and may be involved in the triggering of myocardial ischemia and infarction [17] . Tissue expression and plasma concentrations of inflammatory markers and mediators are increased in patients with cardiovascular disease [18] . Those molecules include CRP [18] , adhesion molecules such as vascular cell adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) [18] [19] [20] [21] , chemokines such as monocyte chemoattractant protein-1 (MCP-1), as well as anti-fibrinolytic agents such as plasminogen activator inhibitor-1 (PAI-1). Upregulation of inflammatory mediators in tissues, such as nuclear factor-kB (NF-kB), activator protein-1 (AP-1), the adhesion molecules VCAM-1, ICAM-1, platelet endothelial cell adhesion molecule and tissue factor [22] , has been demonstrated in experimental hypertension. Hence, strategies targeted to lower blood pressure and reduce vascular inflammation may potentially provide clinical benefits.
In this review, we discuss the role of chronic low-grade inflammation in the context of structural and functional modification in the vasculature in hypertension and its complications, in view of therapeutic intervention to reduce cardiovascular risk.
Renin-angiotensin-aldosterone system: the major mechanism for vascular damage
The activation of the RAAS plays a key role in the development and pathophysiology of cardiovascular diseases. Angiotensin II, one of the final products and main mediators of the system, induces several mechanisms leading to vascular remodeling and injury (Fig. 1) . These include vasoconstriction, cell growth, oxidative stress production, and inflammation. Angiotensin II is primarily involved in the inflammatory process by modulating cytokine release [23] and pro-inflammatory transcription factors such as NF-kB [24] , which in turn regulate adhesion molecule (VCAM-1 and ICAM-1) expression [25] . All these can induce inflammation within the vascular wall, deposition of extracellular matrix, and hypertrophy and/or hyperplasia of vascular smooth muscle cells (VSMCs) [26] . In addition, angiotensin II stimulates the production of PAI-1 [27] , which may contribute not only to the prothrombotic state but also to plaque rupture in atherosclerotic lesions. Angiotensin II also stimulates the activation of matrix metalloproteinases, which can digest the fibrous cap and thereby participate in the triggering of plaque rupture [28] . Reactive oxygen species (ROS) act as signaling molecules modulating vascular tone and structural changes in the microcirculation [29] , as well as exerting effects on the development and progression of atherosclerosis [30] . NAD(P)H oxidase is the major source of vascular ROS and is expressed in endothelial cells, VSMCs, fibroblasts and monocytes/macrophages [31, 32] . Humoral agents, such as angiotensin II and endothelin-1, and inflammatory mediators can modulate basal superoxide production by NAD(P)H oxidase and the expression of NAD(P)H oxidase subunits [33] .
Long-term infusion of non-pressor doses of angiotensin II is able to induce vascular remodeling [34] , and beneficial effects on vascular structure and remodeling have been noted with the inhibition of the RAAS beyond blood pressure lowering [35, 36] . Increased ROS production induced by angiotensin II is involved in the mechanism leading to vascular remodeling, through VSMC proliferation and hypertrophy and collagen deposition [37] . Increased ROS levels in hypertension impair endothelium-dependent vascular relaxation by reducing nitric oxide (NO) bioavailability [38, 39] , and increase vascular contractile responses. Angiotensin II-stimulated NAD(P)H oxidase induces ICAM-1 expression, macrophage infiltration and vascular hypertrophy independently of blood pressure elevation [40] . Macrophages infiltrating the adventitia or the media of blood vessels may mediate oxidative stress generated by NAD(P)H oxidase, also in response to elevated blood pressure [41] ( Fig. 1 ). Mice deficient in monocytes/macrophages present less oxidative stress and less induction of inflammatory molecule upregulation by angiotensin II in the vasculature, and develop less endothelial dysfunction and vascular remodeling [42 ] , suggesting a central role for macrophages and pro-inflammatory mediators in angiotensin II-induced vascular injury.
The activation of mineralocorticoid receptors is emerging as an important contributor to cardiovascular dysfunction, inflammation and damage. These effects may be modified by dietary salt intake. Several animal models have confirmed that aldosterone and other mineralocorticoids can cause injury in the vasculature of the brain, heart and kidneys [43] . Mineralocorticoid antagonism attenuates this damage by mechanisms that appear to be independent of changes in systolic blood pressure, involving direct pro-inflammatory and pro-fibrotic effects [44] [45] [46] [47] .
It is recognized that angiotensin II stimulates endothelin-1 production [48 ] . In particular, angiotensin II-induced NF-kB and AP-1 activation involves in part endothelin receptors [49] . Endothelin-1 itself is an important mediator of chronic inflammation in the vasculature [46, 47, 48 ]. In human VSMCs, endothelin-1 induces the release of interleukin-6 (IL-6) via NF-kB activation [50] . Endothelin-1 activates NAD(P)H oxidase in VSMCs and in blood vessels [51, 52] (Fig. 1) , and ET A receptor antagonism decreases oxidative stress, normalizes hypertrophic remodeling, decreases collagen and fibronectin deposition, and reduces ICAM-1 levels in the vasculature of aldosterone-infused rats [47, 51] . When preproendothelin-1 was transgenically overexpressed in the endothelium, mice exhibited not only blood pressure-independent hypertrophic vascular remodeling and endothelial dysfunction, but also increased activity of NAD(P)H oxidase leading to enhanced oxidative stress and vascular inflammation [52] .
Blockade of the RAAS in hypertensive subjects should result in reduced oxidative stress, inflammatory markers, fibrinolysis and endothelial dysfunction. Angiotensinconverting enzyme inhibitors (ACEIs) reduce PAI-1 levels over a long period of time [53] , and patients treated with angiotensin type 1 receptor blockers present improved endothelial function, diminished plasma concentrations of systemic markers of oxidative stress as well as of tumor necrosis factor-a (TNF-a) and MCP-1, and reduced PAI-1 [54] . In a recent study, angiotensin type 1 receptor blockers appeared to exert stronger systemic anti-inflammatory and anti-aggregatory effects than ACEIs [55] . Patients with essential hypertension treated with a combination of an ACEI and a mineralocorticoid antagonist had a greater reduction in left ventricular hypertrophy than patients treated with either drug alone [56] . In patients with isolated systolic hypertension of the elderly, mineralocorticoid receptor antagonism reduced microalbuminuria to a greater extent than amlodipine, despite a similar reduction in blood pressure [57] . Thus a more complete and selective blockade of the components of the RAAS may be necessary to reduce inflammatory vascular damage in hypertension.
C-reactive protein: marker (or mediator?) of inflammation in hypertension and cardiovascular diseases
CRP is a 115-kDa pentamer expressed almost exclusively by hepatocytes as part of the non-specific acute-phase response to tissue damage, infection, inflammation and malignant neoplasia [58] . Numerous epidemiological studies have shown that the plasma CRP level is a powerful predictor of ischemic cardiovascular events (stroke, peripheral vascular disease, sudden cardiac death and myocardial infarction) in patients with stable or unstable angina, and even among apparently healthy subjects [59] [60] [61] . Elevated CRP levels appear to correlate with softer plaques that are more prone to rupture [59] , and may be useful in targeting medium-risk patients who would benefit from aggressive cardiovascular disease prevention therapies that would otherwise not be employed.
Previous studies have shown increased large artery stiffness to be an additional predictor of both atherosclerosis and cardiovascular risk [62, 63] . Inflammation within the wall of large arteries exerts its vascular effects in part by impairing large artery elasticity and increasing vascular stiffness. Indeed, a correlation between CRP and measures of arterial wave reflection and stiffness in asymptomatic subjects was recently demonstrated [64] . Furthermore, the CRP level is positively associated with systolic blood pressure, pulse pressure, and hypertension [65, 66] . After adjustment for life course confounding and a Mendelian randomization approach, however, elevated CRP levels do not appear to lead to elevated blood pressure [67] . Despite the controversy concerning the relationship of CRP to hypertension, both CRP and blood pressure are independent determinants of cardiovascular risk, and, in combination, each parameter has additional predictive value [65, 66] .
The pathophysiological importance of CRP is far from being fully understood, and whether CRP is a risk factor for or mediator of vascular disease remains a subject of ongoing debate. It is likely that CRP is more than an inflammatory marker of increased cardiovascular disease risk (Fig. 2) , as deposits of CRP have been demonstrated by immunohistochemical staining in atherosclerotic plaques, where it co-localizes with the terminal complement complex and appears to be involved in foam cell formation [68] . CRP promotes monocyte chemotaxis [68] and facilitates low-density lipoprotein uptake by macrophages in vitro [69] . In VSMCs, CRP has been shown to increase angiotensin type 1 receptor number and angiotensin type 1 receptor-mediated ROS formation [70] , as well as activation of the stress-activated protein kinases p38 and c-jun N-terminal kinase (JNK) [71] . In endothelial cells, CRP facilitated the release of PAI-1 [72] and endothelin-1 [73] , increased the expression of cell adhesion molecules [74, 75] , and reduced NO bioavailability [75, 76] . In particular, CRP inhibited endotheliumdependent NO-mediated dilatation in coronary arterioles by producing superoxide from NAD(P)H oxidase via p38 kinase activation [77] . On the other hand, it has recently been reported that CRP per se does not activate endothelial cells: contamination with azide and lipopolysaccharide, rather than CRP, was responsible for the cell activation events [78 ] .
Despite the evidence for the pro-inflammatory actions of CRP, the role of CRP as a modulator of inflammation and thrombosis remains elusive. Indeed, CRP may possess anti-inflammatory actions. CRP inhibits neutrophil activation and adhesion [79, 80] and blocks platelet aggregation in vitro [81] [82] [83] . Accordingly, it has been proposed that distinct isoforms of CRP are formed during inflammation. CRP could dissociate into individual subunits that undergo conformational changes. The resulting CRP isoforms, referred to as modified or monomeric CRP, express several neoepitopes and display properties distinct from those of native CRP [84] [85] [86] . Monomeric CRP antigens were detected in inflamed tissues and in the wall of human normal blood vessels, and display potent prothrombotic activities under low levels of shear, whereas native CRP inhibits platetelet activation and prevents neutrophil-endothelial-cell adhesion and neutrophilplatelet adhesion. Thus monomeric CRP rather than native CRP may precipitate acute coronary syndromes [87 ] .
Thus whether CRP is marker or mediator of cardiovascular risk and disease is still a matter of controversy, as is its power as a marker of ischemic events. Indeed, despite the recent recommendation of the Center for Disease Control and the American Heart Association [88] , critical review of the accumulating evidence now suggests that CRP is a relatively poor predictor that does not contribute usefully in this regard [89] . This does not imply, however, that human CRP may not be a pro-inflammatory molecule under certain circumstances, as well as a marker to consider in medium-risk cardiovascular patients.
Activators of peroxisome proliferatoractivated receptors: novel anti-inflammatory cardiovascular protectors
Peroxisome proliferator-activated receptors (PPARs) are nuclear receptors that modulate the functions of many target genes. Three PPARs, a, b/d and g, have been demonstrated. PPARa is involved in fatty acid oxidation and is expressed in liver, kidney and skeletal muscle; PPARb/d is ubiquitous and regulates lipid metabolism; and PPARg plays a role in fat cell differentiation, lipid storage and insulin sensitivity [90] . PPARs are present in cardiovascular tissues, including the endothelium, smooth muscle cells, macrophages, and heart [91] [92] [93] . Fibrates (hypolipemic agents) and fatty acids activate PPARa, and thiazolidinediones or glitazones (antidiabetic drugs) stimulate PPARg [94] ; however, the endogenous ligands of PPARs remain unknown.
PPARa and PPARg have increasingly been demonstrated to exert cardiovascular protective effects, independent of their metabolic actions [92, 93] . Whereas the metabolic effects of PPARs are mediated by the activation of a PPAR-responsive element present in the promoter regions of different genes, the cardiovascular protective actions may result from anti-inflammatory and antioxidant actions mediated by trans-repression of pro-inflammatory and pro-oxidant genes. PPAR activators lowered blood pressure, induced favorable effects on the heart, and corrected vascular structure and endothelial dysfunction in several rodent models of hypertension, including genetic models [95] , and models of angiotensin II-dependent [22, 96, 97] and endothelin-1-dependent [98] hypertension. These effects were associated with antioxidant, anti-inflammatory, antiproliferative, antihypertrophic, and antifibrotic effects [99] . In particular PPARa ligands inhibit production of IL-6 and prostaglandins, and expression of cyclooxygenase-2. These effects occur as a consequence of PPARa-induced inhibition of signaling by the pro-inflammatory mediator NF-kB ( Fig. 1 ) and induction of apoptosis [100] . PPARa activators also downregulate cytokine-induced genes, such as those encoding VCAM-1 and tissue factor, in endothelial cells [101] , as well as reducing plasma concentrations of the cytokines interferon-g and TNF-a in patients with hyperlipoproteinemia IIb [102] . Furthermore, PPARa activators reduce angiotensin II-induced NAD(P)H oxidase activity and levels of inflammatory molecules [96] , and increase endothelial NO synthase expression in bovine aortic endothelial cells [103] (Fig. 1) . PPARg activators inhibit the expression of TNF-a, IL-6, IL-1b [104] , inducible NO synthase, matrix metalloproteinase-9 and scavenger receptor A in monocytes [105] , through inhibition of the transcription factors AP-1, STAT (signal transducer and activator of transcription) and NF-kB (Fig. 1) . Moreover, PPARg activators improve endothelial function through a transcriptional mechanism unrelated to the expression of endothelial NO synthase [106] . Different studies have also demonstrated that activation of PPARg exerts anti-atherosclerotic actions [107] . PPARa, through its effect to lower triglycerides as well as its anti-inflammatory action, also prevents the progression of atherosclerosis [108] . Therefore, we [92, 93] and others [107] have proposed that activators of PPARs may become therapeutic agents useful in the prevention of cardiovascular disease beyond their effects on carbohydrate and lipid metabolism.
Conclusion
A growing body of evidence suggests that inflammation participates in the development and pathogenesis of hypertension. Hypertension may be considered a low-grade inflammatory disease. Selective antagonism of the RAAS reduces inflammation in hypertension beyond blood pressure reduction. Development of new therapeutic tools (such as PPAR agonists) to interfere with the inflammatory mechanisms in hypertension, and the evaluation of the efficacy of anti-inflammatory treatments, will allow progress in our ability to treat hypertension and its cardiovascular complications.
